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INTRODUCTION
Certain psychiatric disorders are known to be associated 
with low bone mineral density (BMD), including schizoph-
renia, schizoaffective states, and major depressive disorder.
1-5 
The nature of the relationship between psychiatric disorders 
and psychotropic medications and bone metabolism is unre-
solved; however, there is growing evidence that medications 
used to treat disorders are associated with low BMD or alter-
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ations in the neuroendocrine system that influences bone tur-
nover.
5 Several reports suggested that patients receiving long-
term antipsychotics show reduced BMD.
5,6 Low dietary cal-
cium intake, smoking, polydipsia, and antipsychotic-related 
hyperprolactinemia have been implicated.
3 
In patients with bipolar disorder, several lines of evidence 
have suggested that lithium has a negative impact on bone me-
tabolism with an association of hyperparathyroidism.
5 How-
ever, there have been no reports examining the relationship 
between valproate as a mood stabilizer and BMD in bipolar 
disorder.
5,7 A few studies have found that BMD was decreased 
in epileptic patients who received valproate.
8-11 Valproate can 
be used to treat both bipolar disorder and epilepsy; however, 
to our knowledge no study of the relationship between valpro-
ate and BMD in bipolar disorder has been reported. Valproate 
is generally the first drug of choice when selecting a mood st-
abilizer, however mood stabilizers are frequently combined 
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with antipsychotic medications in clinical practice. 
In this report, we investigated BMD and markers of bone 
metabolism in female bipolar patients treated with a long-term 
combination of valproate and low-dose atypical antipsychotics. 
METHODS
Subjects
Nineteen subjects were eligible for participation. Subjects in-
cluded in the study were 1) bipolar patients diagnosed accord-
ing to the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition criteria; 2) patients receiving maintaining 
therapy with valproate and low-dose atypical antipsychotics 
for at least 2 years; 3) premenopausal women; and 4) ambu-
latory outpatients with normal activity and nutritionally ade-
quate diets. Exclusions included 5) pregnant or breast-feed-
ing women; 6) alcoholism or drug abuse; 7) comorbid medical 
diseases known to affect bone metabolism such as hepatic or 
renal disorders, hypothyroidism, or malabsorption; 8) a his-
tory of medication treatments that can affect bone turnover (e.g., 
vitamin A, glucocorticoids, oral contraceptives, thiazides, cal-
citonin, vitamin D, calcium supplements, or biphosphonates). 
Written informed consent was obtained from all subjects af-
ter they were given information about the study. The Korea Uni-
versity Institutional Review Board approved this study.
Clinical and biochemical evaluation
Demographic and clinical data were collected including age 
of disease onset, duration of illness, and dose and duration of 
medication. The Brief Psychiatric Rating Scale, Young Mania 
Rating Scale, Hamilton rating scale for depression, and Clini-
cal Global Impression scores were applied. Other variables in-
cluded smoking, alcohol, coffee drinking, exercise, diet, his-
tory of fracture/fall, and menstrual irregularity. Bone format-
ion and resorption markers were assessed for calcium, phos-
phorus, alkaline phosphatase, osteocalcin, 25(OH)-vitamin 
D, parathyroid hormone (PTH), and urine deoxypyridino-
line. Blood valproate levels, prolactin, and circulating levels 
of gonadal hormones including prolactin, estradiol, luteniz-
ing hormone, follicle-stimulating hormone, progesterone and 
testosterone were also assessed. 
Bone mineral density measurement
The BMD was measured at the lumbar spine and various 
femur sites using dual-energy X-ray absorptiometry (DEXA) 
(Hologic Discovery-A bone densitometer; Hologic, Inc., Bed-
ford, MA, USA). T-scores and Z-scores suggested by World 
Health Organization criteria
12 were calculated in all subjects. 
Osteopenia was defined as less than -1.0 and greater than -2.5. 
Osteoporosis was defined as -2.5 or lower, meaning a bone 
density that was two and a half standard deviations below the 
mean of an average thirty-year-old woman. The Z-score was the 
number of standard deviations above or below the mean for age- 
and sex-matched controls. 
Statistical analysis
Comparison of all demographic, biochemical parameters 
and densitometrical parameters were conducted using the 
Mann-Whitney U test between subjects with abnormal and 
normal DEXA scans. Nonparametric repeated measure analy-
ses with Wilcoxon’s signed rank post-hoc tests were applied for 
comparison between the BMD of femurs and lumbar spine. 
Correlation between clinical, biochemical and BMD measu-
rements was tested by a Spearman rank correlation. Within gr-
oups, simple linear regression was used to determine the asso-
ciation between BMD and various risk factors including age, 
weight, duration of medication, alcohol, smoking, coffee, and 
daily exercise as well as biochemical indices of bone metabo-
lism. Multiple linear regressions with significant variables were 
used to determine the relating factors. The SPSS 15.0 package 
program was used in the statistical analysis. A value of p< 
0.05 was considered statistically significant. 
RESULTS
Nine (47.4%) out of all 19 subjects showed decreased BMD 
(osteopenia/osteoporosis defined as T-score <-1.0) on DEXA 
scans. Two of the nine subjects (22.2%) had osteoporosis. To-
tal body BMD of whole study subjects was -0.95±1.19 g/cm
2, 
which was lower than the BMD mean value of adult Korean 
women shown in previous reports (1.16±0.11 g/cm
2 aged in 
their thirties and 1.08±0.14 g/cm
2 aged in their forties). The 
T-scores of the right and left femurs were -0.18±1.26 and 
-0.24±1.33, respectively, and the T-score of the lumbar spine was 
-0.30±1.22.
13,14 T-scores for subjects with abnormal DEXA 
scans were -1.988 compared to subjects with normal DEXA 
scans of -0.050. 
The mean age of subjects was 39.68±10.17 years. The aver-
age body mass index (BMI) was in the overweight range at 
24.33±3.63 kg/m
2. The antipsychotics used for concomitant 
treatment were risperidone at a dose range of 0.5-1.5 mg (n= 
9), olanzapine with a dose range of 2.5-5 mg (n=4), and que-
tiapine with a dose range of 25-100 mg (n=6) (Table 1). 
BMD levels were found to be lower in the proximal femur 
(femur neck and trochanter) than in the lumbar spine (p= 
0.000). In comparison between both groups, femoral neck Z-
scores of subjects with abnormal DEXA scans were statisti-
cally lower than those of subjects with normal DEXA scans 
(p=0.021 and p=0.001, respectively). Z-scores for the troch-
anter (right and left) and lumbar spine were lower in subjects 258  Psychiatry Investig 2011;8:256-261
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with abnormal DEXA scans, however these differences did 
not have a statistical significance (p=0.360, p=0.055, and p= 
0.101, respectively). BMD values for the two groups are shown 
in Table 2. 
When comparing the clinical and laboratory findings, no 
variables were different between the two groups for any of the 
following demographic and clinical parameters: marital sta-
tus (p=0.807), occupation (p=0.489), family history (p=1.000), 
suicide history (p=1.000), exercise (p=0.581), alcohol (p= 
1.000) or smoking (p=1.000). Subjects with abnormal DEXA 
scans tended to have longer medication lengths (53.67±17.18 
vs. 42.70±28.48, p=0.447) although this was not significant. 
The mean values for all bone turnover biochemical markers 
were within normal ranges; however some values showed sig-
nificant differences between the two groups (Table 3). Subjects 
showing abnormal DEXA scans had high phosphorus (3.99 
vs. 3.32, p=0.008), and low testosterone (0.20 vs. 0.49, p= 
0.028) levels relative to subjects with normal DEXA scans. 
Subjects with abnormal DEXA scans also showed increased 
levels of osteocalcin and deoxypyridinoline, but these did not 
quite reach statistical significance. Serum 25(OH) vitamin D 
and PTH levels tended to be lower in abnormal DEXA scan 
subjects with no statistical significance. 
There was a significant negative correlation between phos-
phorus level and both the left and right femur neck BMDs 
(r=-0.503, -0.552, p<0.05). PTH had positive correlation with 
both femur neck BMDs (r=0.501, r=0.520, p<0.05) and oste-
ocalcin showed a negative correlation with the left femur neck 
BMD (r=0.548, p<0.05). However, disease-related factors (e.g., 
duration and severity of illness, number of episodes, and du-
ration of valproate use) as well as demographic factors did 
not correlate with BMD of the femur and lumbar spine. Fac-
tors contributing to the variance in BMD were identified by 
subsets of linear regression. None of the identified factors, 
Table 1. Clinical characteristics of the study population
Parameters
Total subjects
(N=19)
Age (mean±SD, years) 039.68±10.17
Education (mean±SD, years) 012.16±3.13
Height (mean±SD, cm) 159.95±3.98
Weight (mean±SD, kg)  061.16±7.17
BMI (mean±SD, kg/m
2) 024.33±3.63
Exercise*
Regular (N) 7
Irregular (N) 4
None (N) 8
Onset age (mean±SD, years) 031.84±9.92
No. of episodes (mean±SD, N) 003.79±2.02
No. of admissions (mean±SD, N) 002.74±2.02
Medication duration (mean±SD, months) 049.47±23.52
BPRS (mean±SD) 025.53±2.95
YMRS (mean±SD) 003.37±2.45
HAMD (mean±SD) 008.41±6.35
Valproate dose (mean±SD, mg/day) 527.78±157.39
Concomitant antipsychotics 
   Risperidone, N (range) 9 (0.5-1.5 mg)
   Olanzapine, N (range) 4 (2.5-5 mg)
   Quetiapine, N (range) 6 (25-100 mg)
*regular exercise, 2 times or more/week, Irregular exercise, 1 time or 
less/week. BMI: Body Mass Index, BPRS: Brief Psychiatric Rating 
Scale, YMRS: Young Mania Rating Scale, HAMD: Hamilton De-
pression Rating Scale
Table 2. BMD of the subjects with abnormal and normal DEXA 
scans
Site of bone mass
Abnormal DEXA 
scans (N=9)
(mean±SD)
Normal DEXA 
scans (N=10)
(mean±SD)
Total body BMD -0.98±1.19 -0.05±0.68
Femur, right
Neck 
BMD (g/cm
2)*** 0.70±0.08 0.87±0.098
Z-score** -0.06±0.94 1.070±0.80
Trochanter
BMD (g/cm
2)*** 0.61±0.07 0.72±0.05
Z-score 0.60±1.64 1.02±0.61
Total 
BMD (g/cm
2)*** 0.81±0.10 0.97±0.06
Z-score** 0.10±1.01 1.22±0.51
Femur, left
Neck 
BMD (g/cm
2)*** 0.68±0.72 0.85±0.86
Z-score** -0.25±0.74 0.88±0.74
Trochanter
BMD (g/cm
2)** 0.62±0.07 0.74±0.05
Z-score 0.25±0.91 1.16±0.67
Total 
BMD (g/cm
2)*** 0.82±0.09 1.00±0.07
Z-score** 0.18±0.85 1.42±0.61
Lumbar spine
BMD (g/cm
2)** 0.93±0.69 1.07±0.11
Z-score 0.13±0.92 0.83±0.93
**p<0.01, ***p<0.001. DEXA: Dual-energy X-ray absorptiometry, 
BMD: bone mineral density; defined according to the World Health 
Organization operational definition (i.e.) BMD T-score -2.5 for os-
teoporosis and a BMD T-score between 1 and -2.5 for osteopenia. 
Mann-Whitney U testJ Yang et al. 
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including BMI, group (subjects with either abnormal vs. nor-
mal DEXA scans), phosphorus, and osteocalcin, had an ef-
fect on the femur and lumbar BMD values (p>0.05). 
DISCUSSION
These results suggest that long-term treatment with val-
proate combined with a low-dose atypical antipsychotic may 
adversely affect BMD and bone metabolism in premenopau-
sal women with bipolar disorder. Decreased BMD was more 
prominent in the proximal femur than in the lumbar spine, and 
the biochemical markers that reflect bone metabolism may 
be related to osteoporosis or osteopenia. 
The most common form of bone loss is postmenopausal 
osteoporosis related to estrogen deficiency. A main cause of se-
condary osteoporosis is disease-induced or drug-induced bone 
loss.
5 Studies associated with BMD in psychiatry have focus-
ed mainly on schizophrenic patients. In women suffering from 
schizophrenia, the associated antipsychotic-induced hyperp-
rolactinemia, hypogonadism, and resulting estrogen defici-
ency may reduce bone density.
15 All conventional and atypical 
antipsychotics, which are potent D2 inhibitors and cause pro-
lactin elevation, have been associated with decreased BMD.
6,16 
However, there is some controversy as to whether the medic-
ation or the disease itself causes the hyperprolactinemia and 
decreased BMD.
3,5,6,17,18 In depression, elevation in cortisol le-
vels contributes to low BMD through decreased bone turn-
over, and low estrogen level is associated with decreased 
BMD.
4,5 However, few studies have examined the relationship 
between bipolar disorder or medication for this disease and 
BMD. In one study, 60% of chronic psychiatric inpatients who 
were maintained on long-term valproate treatment had os-
teoporosis or osteopenia, although the diagnoses of these pa-
tients were not mentioned.
19 In our results, almost half of the 
subjects showed decreased BMD with long-term valproate 
treatment combined with a low-dose atypical antipsychotic in 
premenopausal women with bipolar disorder. Previous stud-
ies have suggested that a reduction in BMD in epileptic pa-
tients using enzyme-inducing anticonvulsants was caused by 
an increase in vitamin D catabolism.
9,10,20,21 Valproate may also 
reduce BMD by increasing vitamin D catabolism or affecting 
bone mineralization.
19,22 However, valproate is not a hepatic en-
zyme inducer and therefore the decrease in bone density is ex-
pected to occur via another mechanism.
8,22,23 Valproate may 
reduce BMD by inducing reversible Fanconi syndrome, caus-
ing renal tubular dysfunction resulting in excess calcium loss.
9,22 
Lack of correlation between vitamin D levels and BMD in our 
study may support a non-vitamin D-mediated mechanism 
of action for valproate on the skeleton as has been previously 
suggested.
21,22 In addition to valproate, our subjects also took 
antipsychotics that can cause hyperprolactinemia, which may 
further increase their risk for low BMD. However, the level of 
prolactin was within the normal range (18.57±10.68 ng/mL) 
in all subjects,
18 and comparison between the subjects with 
abnormal and normal DEXA scans did not show significant 
differences. Therefore, hyperprolactinemia cannot be a suffici-
ent explanation for decreased BMD. 
In our subjects, BMD was lower in the proximal femur than 
that in the lumbar spine. Valproate treatments in women with 
epilepsy have reduced BMD at the femoral neck, but not at the 
Table 3. Laboratory findings of the subjects with abnormal and normal DEXA scans
Laboratory data Reference range
Abnormal DEXA scans (N=9)
(mean±SD)
Normal DEXA scans (N=10)
(mean±SD)
Calcium (ng/dL) 8.5-10.5 09.3±0.1 09.4±0.3
Phosphorus (ng/dL)* 2.5-4.5 04.0±0.5 03.3±0.4
ALP (IU/L) 44-147 60.8±17.2 61.3±12.4
25(OH) vitamin D (ng/mL) 25-66 22.8±5.9 31.9±10.0
Parathormone (pg/mL) 6-40 23.2±13.0 29.2±11.4
Osteocalcin (ng/mL) 2.5-13 06.0±3.0 04.1±1.2
Deoxypyridoline (ng/mL) 3-8 05.3±2.1 04.4±1.0
Prolactin (ng/mL) 2.8-29 28.4±27.9 11.7±6.5
FSH (mIU/mL) 2-11 14.6±5.5 08.0±5.0
LH (mIU/mL) 2-11 11.9±8.7 12.1±8.2
Estradiol (pg/mL) 11-110 41.3±44.5 68.5±66.5
Progesterone (pg/mL) 0-20 03.9±8.2 03.1±4.4
Testosterone (ng/mL)* 0.2-0.6 00.2±0.2 00.5±1.2
Valproate serum level (ng/mL) 50-100 50.6±14.8 57.4±17.4
*p<0.05. ALP: alkaline phosphatase, DEXA: dual-energy X-ray absorptiometry, FSH: follicle-stimulation hormone, LH: luteinizing hormone260  Psychiatry Investig 2011;8:256-261
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lumbar spine.
20 Moreover, trabecular bone rather than corti-
cal BMD may be more affected in patients who are taking 
valproate for bipolar disorder. This would be similar to the re-
sults demonstrating lower density of the trabecular bone but 
not cortical bone in patients with depressive disorder.
4 
Comparison between the two groups by BMD scores sh-
owed no significant difference in any clinical parameter. Sub-
jects with abnormal DEXA scans showed a relatively longer 
duration of medication, however the correlation was not sig-
nificant. Our subjects took their medications for over 2 years. 
Previous studies have suggested an association between the 
duration of valproate medication and osteoporosis.
8,20,22,23 Th-
erefore, a more comprehensive study will be needed to ad-
dress this conflicting observation. 
For all subjects, the mean for all biochemical makers were 
within normal ranges. In comparison, subjects with abnormal 
DEXA scans showed a significant decrease in phosphorous 
levels and tended to have a decrease in osteocalcin levels. Os-
teocalcin, which is produced by osteoblasts, is a marker pro-
tein of bone matrix synthesis and also plays a key role in the re-
gulation of bone resorption. Oner et al.
23 found high normal 
osteocalcin levels in patients receiving valproate monotherapy 
in epilepsy patients. Our results suggest that phosphorus and 
osteocalcin may be related with bone loss in female bipolar 
patients treated with valproate and atypical antipsychotics. 
Interestingly, only testosterone showed a significantly lower 
level in subjects with abnormal DEXA scans relative to nor-
mal subjects. Androgens, which are similar to estrogen, have 
also been shown to indirectly influence bone metabolism by 
several potentially interrelated mechanisms. Due to its effect 
on osteoblastic activity, low levels of testosterone are correlat-
ed with osteoporosis in schizophrenic patients.
24 In addition, 
Halbreich et al.
3 found a correlation between BMD and testo-
sterone in medicated men with psychiatric illnesses. Therefore, 
testosterone may play a role in low bone density.
The limitations of our report include its cross-sectional de-
sign rather than the preferred prospective, double blind study. 
The relatively small number of subjects is also a drawback. In 
addition, those patients taking valproate also were taking aty-
pical antipsychotics that could increase serum prolactin, wh-
ich may further increase their risk for low BMD. Studying 
BMD in patients with psychiatric illness may be much more 
difficult than studies in other populations (e.g. epilepsy) be-
cause mood stabilizers are frequently combined with anti-
psychotics in patients with bipolar disorder in clinical prac-
tice. We were unable to adjust for other potential confounders 
including race, although our study excluded as many con-
founding variables as possible. 
In conclusion, this is the first report describing decreased 
BMD and changed biochemical markers of bone turnover in 
premenopausal bipolar patients on maintenance treatment 
with valproate and a low-dose atypical antipsychotic. Long-
term maintenance treatment with valproate combined with a 
low-dose atypical antipsychotic may adversely affect BMD in 
premenopausal women with bipolar disorder. All bone me-
tabolism biochemical markers were within normal ranges; as 
such we could not find an association between low BMD and 
biochemical makers of bone metabolism. Additional prospec-
tive studies with a larger population are warranted to better 
understand the exact mechanism of low BMD and biochemi-
cal changes in bipolar patients treated with valproate and aty-
pical antipsychotics.
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